News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UCB Group’s Cimzia Cuts Arthritis Joint Damage at 16 Weeks
June 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 12 (Reuters) - UCB's drug Cimzia stops structural damage to joints in patients with rheumatoid arthritis as soon as 16 weeks after the start of treatment, according to new data presented on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Job Trends
Opinion: Innovation wins the contract. Complexity loses the renewal
July 1, 2026
·
3 min read
·
Antonio Serrano
Immunology and inflammation
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
June 30, 2026
·
2 min read
·
Tristan Manalac
